Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Belsomra (suvorexant by Year
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M) ($M)
Merck Belsomra (suvorexant: $82M in FY2025, up 13.9% from a year earlier.
Where the FY2025 figure comes from
“|| Belsomra | 186 | 222 | -16 | 82 | 72 | 13 | 104 | 150 | -31”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 82 | +13.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 72 | -11.1% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 81 | +2.5% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 79 | +1.3% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 78 | -3.7% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 81 | -12.0% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 92 | -4.2% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 96 | -2.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 98 | +16.7% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 84 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up belsomra (suvorexant
Cite this data
StockData. (2026). Merck Belsomra (suvorexant ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-belsomra-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.